Venn Life Sciences offers drug development consultancy and services to help bring products to the market quickly and efficiently.
The European Clinical Trials Regulation (Regulation (EU) No 536/2014) on clinical trials on medicinal products for human use requires that for all clinical trials carried out in the EU, a sponsor or a legal representative of the sponsor must be legally registered within the...
Venn Data Management services/capabilities span the data life cycle from collection to archival. Data drives the whole clinical development process. A high-quality dataset is therefore essential for the success of your drug. Our clinical data managers provide a smooth less flow from first patient...
By offering tailor made solutions with a strong focus on accuracy and quality, our clients can keep a track on timelines and costs are kept to a minimum. Our statisticians provide statistical support along the full development cycle of the drug, from early development...
To appropriately manufacture a pharmaceutical or biological product, a well-defined drug substance and product, manufacturing process and test methods must be developed in order to ensure that the product is safe, effective and consistent between batches. Which is a prerequisite to get regulatory approval...
This enables us to create, plan and execute drug development programmes effectively for our global customers, ranging from virtual start-up companies to established pharma companies. Venn’s capabilities and expertise includes CMC, Non-Clinical, Clinical Pharmacology and Development, Statistics, Study Design and Methodology, Data Management, RTSM...
In drug development, a proper clinical development strategy, implemented at an early stage of product development, helps to guide the success (and cost-effectiveness) of the product development. To understand the kinetics of a drug in terms of absorption, distribution, metabolism and elimination (ADME), pharmacokinetic...
Non-clinical testing is conducted throughout all phases of drug development to assess the safety profile and pharmacokinetic/toxicokinetic (PK/TK) characteristics of drug candidates. If performed well, it can identify key ‘knock-out’ criteria, maximizing the chances of success in subsequent stages of development. Strategies for the...